Journal Watch · Journal for ImmunoTherapy of Cancer · 2026

Fluorination augments tumor engagement and antitumor immunity of a D-peptide-based radiotheranostic agent for combinatorial immune checkpoint blockade therapy.

Additionally, [<sup>177</sup>Lu]D3-6 boosted both local and systemic antitumor immunity and, in combination with anti-programmed cell death protein-1 therapy, elicited superior tumor inhibition.<h4>Conclusion</h4>This study highlights the potential of fluorinated D-peptide radiopharmaceuticals as powerful PD-L1 targeting radiotheranostics, enabling more effective systemic antitumor efficacy in RPT and ICB combination therapy.

Zhang S, Liu C, Lu Q et al.Journal for ImmunoTherapy of Cancer3 min readPharma relevance 75/100

DOI: 10.1136/jitc-2025-013732PMID: 41802811Study type: preclinical (animal / model) study

TL;DR

Additionally, [<sup>177</sup>Lu]D3-6 boosted both local and systemic antitumor immunity and, in combination with anti-programmed cell death protein-1 therapy, elicited superior tumor inhibition.<h4>Conclusion</h4>This study highlights the potential of fluorinated D-peptide radiopharmaceuticals as powerful PD-L1 targeting radiotheranostics, enabling more effective systemic antitumor efficacy in RPT and ICB combination therapy.

Key findings

  • Their in vivo performance was assessed by positron emission tomography (PET)/CT imaging in tumor-bearing mice and subsequently in patients with cancer.
  • The therapeutic efficacy of the corresponding <sup>177</sup>Lu-labeled fluorinated radiopharmaceuticals was further investigated to verify their potential in enhancing antitumor immunity.<h4>Results</h4>[<sup>68</sup>Ga]D3-6, which incorporates a pentafluorinated phenylalanine residue, exhibited optimal tumor uptake and prolonged retention, achieving 22.43±1.63%ID/g at 4 hours post-injection.
  • A preliminary clinical study further validated its diagnostic efficacy across multiple cancers.
  • Additionally, [<sup>177</sup>Lu]D3-6 boosted both local and systemic antitumor immunity and, in combination with anti-programmed cell death protein-1 therapy, elicited superior tumor inhibition.<h4>Conclusion</h4>This study highlights the potential of fluorinated D-peptide radiopharmaceuticals as powerful PD-L1 targeting radiotheranostics, enabling more effective systemic antitumor efficacy in RPT and ICB combination therapy.

Numbers at a glance (from the abstract)

1.63%

Every figure above is taken verbatim from the abstract below. Check the full text for denominators, confidence intervals and subgroup detail.

What they did

We previously reported [<sup>68</sup>Ga]/[<sup>64</sup>Cu]DPA, which exhibited favorable in vivo stability. Nevertheless, its inadequate tumor retention hampers therapeutic efficacy and immune activation, highlighting the need for further optimization to achieve sustained target engagement.<h4>Methods</h4>Herein, fluorine modification-directed rational design was used to optimize DPA's target engagement and retention, thereby boosting its immune-activating potential in RPT. Following two rounds of screening, a series of fluorinated D-peptides was synthesized.

Full abstract (original)

Background: <h4>Background</h4>Programmed death-ligand 1 (PD-L1)-targeted radiopharmaceutical therapy (RPT) combined with immune checkpoint blockade (ICB) represents a promising combinatorial treatment because of the "magic" bystander and abscopal effects of RPT. However, the overall efficacy of this combinatorial approach is often constrained by limited tumor retention and insufficient accumulation of existing radiopharmaceuticals. D-peptides, with their superior metabolic stability, offer a promising modality to overcome these limitations.

What they did: We previously reported [<sup>68</sup>Ga]/[<sup>64</sup>Cu]DPA, which exhibited favorable in vivo stability. Nevertheless, its inadequate tumor retention hampers therapeutic efficacy and immune activation, highlighting the need for further optimization to achieve sustained target engagement.<h4>Methods</h4>Herein, fluorine modification-directed rational design was used to optimize DPA's target engagement and retention, thereby boosting its immune-activating potential in RPT. Following two rounds of screening, a series of fluorinated D-peptides was synthesized.

Results & conclusions: Their in vivo performance was assessed by positron emission tomography (PET)/CT imaging in tumor-bearing mice and subsequently in patients with cancer. The therapeutic efficacy of the corresponding <sup>177</sup>Lu-labeled fluorinated radiopharmaceuticals was further investigated to verify their potential in enhancing antitumor immunity.<h4>Results</h4>[<sup>68</sup>Ga]D3-6, which incorporates a pentafluorinated phenylalanine residue, exhibited optimal tumor uptake and prolonged retention, achieving 22.43±1.63%ID/g at 4 hours post-injection. A preliminary clinical study further validated its diagnostic efficacy across multiple cancers. Additionally, [<sup>177</sup>Lu]D3-6 boosted both local and systemic antitumor immunity and, in combination with anti-programmed cell death protein-1 therapy, elicited superior tumor inhibition.<h4>Conclusion</h4>This study highlights the potential of fluorinated D-peptide radiopharmaceuticals as powerful PD-L1 targeting radiotheranostics, enabling more effective systemic antitumor efficacy in RPT and ICB combination therapy.

Abstract © the authors / Journal for ImmunoTherapy of Cancer (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1136/jitc-2025-013732 · PubMed 41802811.

Why it matters for pharma & biotech

  • Directly relevant to teams in targeted oncology / immuno-oncology — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: targeted oncology / immuno-oncology

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The work is preclinical. Results in animal or cell models frequently do not translate directly to human efficacy or safety.

Frequently asked questions

What did this Journal for ImmunoTherapy of Cancer study find?

Additionally, [<sup>177</sup>Lu]D3-6 boosted both local and systemic antitumor immunity and, in combination with anti-programmed cell death protein-1 therapy, elicited superior tumor inhibition.<h4>Conclusion</h4>This study highlights the potential of fluorinated D-peptide radiopharmaceuticals as powerful PD-L1 targeting radiotheranostics, enabling more effective systemic antitumor efficacy in RPT and ICB combination therapy.

What type of study is this?

It is a preclinical (animal / model) study, published in Journal for ImmunoTherapy of Cancer in 2026. We previously reported [<sup>68</sup>Ga]/[<sup>64</sup>Cu]DPA, which exhibited favorable in vivo stability.

Where can I read the original paper?

The original is at the publisher via DOI 10.1136/jitc-2025-013732. PubMed ID: 41802811. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Zhang S, Liu C, Lu Q et al.. Fluorination augments tumor engagement and antitumor immunity of a D-peptide-based radiotheranostic agent for combinatorial immune checkpoint blockade therapy.. Journal for ImmunoTherapy of Cancer (2026). DOI: 10.1136/jitc-2025-013732.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/fluorination-augments-tumor-engagement-and-antitumor-immunity-of-a-d-pep-013732/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides